QCM
MREO

QRG Capital Management’s Mereo BioPharma MREO Stock Holding History

QRG Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,503
Closed -$5.63K – 1181
2025
Q4 		$5.63K Buy
+13,503
New +$25.7K ﹤0.01% 1077

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

QRG Capital Management's MREO Position: Q1 2026 in Review

QRG Capital Management sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 13,503 shares — an estimated $5.63K sold.

QRG Capital Management first reported a position in MREO in Q4 2025 and held it in 1 quarter. The position peaked at $5.63K in Q4 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • QRG Capital Management reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
  • QRG Capital Management sold 13,503 Mereo BioPharma shares in Q1 2026, an estimated $5.63K.
  • QRG Capital Management first reported a position in Mereo BioPharma in Q4 2025 and held it in 1 quarter.
  • QRG Capital Management's Mereo BioPharma position peaked at $5.63K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on QRG Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.